title: Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
abstract: OBJECTIVE
  Compared with radiotherapy alone, concurrent chemoradiotherapy significantly improves survival rates for patients with squamous cell carcinoma of the head and neck. The aim of this study was to retrospectively evaluate the efficacy, toxicity and long-term prognosis of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil chemotherapy.
  
  
  METHODS
  A total of 140 patients were enrolled and evaluated. Patients were received two cycles of docetaxel, cisplatin and 5-fluorouracil chemotherapy (docetaxel [50 mg/m(2): Day 1], cisplatin [60 mg/m(2): Day 4] and continuous 5-fluorouracil [600 mg/m(2)/day: Days 1-5]) during definitive radiotherapy.
  
  
  RESULTS
  The overall response rate was 97.1%. The 3 and 5-year overall survival rates were 83.3 and 79.2%, respectively. The 3 and 5-year disease-specific survival rates were 84.2 and 80.0%, respectively. Among patients with laryngeal or hypopharyngeal carcinoma, the 5-year laryngectomy-free survival rate was 64.9%.
  
  
  CONCLUSIONS
  Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil showed excellent survival and organ preservation rates for the patients with locally advanced squamous cell carcinoma of the head and neck.
authors.affiliation: *Department of Otorhinolaryngology and Head and Neck Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan. komatsu3@yokohama-cu.ac.jp.
authors.forename: Masanori
authors.initials: M
authors.lastname: Komatsu
authors.forename: Osamu
authors.initials: O
authors.lastname: Shiono
authors.forename: Takahide
authors.initials: T
authors.lastname: Taguchi
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Sakuma
authors.forename: Goushi
authors.initials: G
authors.lastname: Nishimura
authors.forename: Daisuku
authors.initials: D
authors.lastname: Sano
authors.forename: Naoko
authors.initials: N
authors.lastname: Sakuma
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Yabuki
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Arai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Junichi
authors.initials: J
authors.lastname: Isitoya
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Oridate
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil
keywords: 5-fluorouracil; chemoradiotherapy; cisplatin; docetaxel; head and neck squamous cell carcinoma